Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus‐based study

In the era of potentially disease‐modifying agents such as Janus kinase inhibitors, accurate grading and differentiation of bone marrow (BM) fibrosis has become more relevant to assess staging of disease and therapeutic effects. However, different fibrosis grading models have been used in the past without uniformity, including the proposal by the World Health Organization. Current scoring systems are based only on reticulin fibrosis. Therefore, additional assessment of collagen and the grade of osteosclerosis appear to be essential to discriminate all components of the complex BM fibrous matrix.

[1]  H. Kantarjian,et al.  Long-Term Effects of Ruxolitinib on Bone Marrow Morphology in Patients With Myelofibrosis and Comparison to Best Available Therapy , 2014 .

[2]  S. Ascani,et al.  Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms , 2014, Modern Pathology.

[3]  S. Rodig,et al.  High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms , 2014, Modern Pathology.

[4]  M. Ehinger,et al.  World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience , 2013, American journal of hematology.

[5]  H. Kantarjian,et al.  Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy , 2013 .

[6]  D. Knowles,et al.  Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage , 2013, Modern Pathology.

[7]  J. Ben-Ezra,et al.  Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis , 2013, Cancer.

[8]  G. Garcia-Manero,et al.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes , 2013, Annals of Hematology.

[9]  S. Bosari,et al.  The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis , 2012, Modern Pathology.

[10]  M. Cazzola,et al.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.

[11]  T. Barbui,et al.  Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. , 2012, Blood.

[12]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[13]  Xingmin Feng,et al.  Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents , 2011, British journal of haematology.

[14]  R. Hoffman,et al.  Clinical and laboratory features of myelofibrosis and limitations of current therapies. , 2011, Clinical advances in hematology & oncology : H&O.

[15]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[16]  M. Cazzola,et al.  Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  U. Gianelli,et al.  Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. , 2008, Blood.

[18]  A. Ganser,et al.  Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.

[19]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[20]  B. Bain,et al.  Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres , 2007, British journal of haematology.

[21]  N. Kröger,et al.  Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. , 2007, Experimental hematology.

[22]  J. Thiele,et al.  Classification of Ph-Negative Chronic Myeloproliferative Disorders – Morphology as the Yardstick of Classification , 2007, Pathobiology.

[23]  J. Thiele,et al.  Myelofibrosis – What’s in a Name? , 2007, Pathobiology.

[24]  H. Deeg,et al.  Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  H. Deeg,et al.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.

[26]  J. Vardiman,et al.  Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. , 2006, Best practice & research. Clinical haematology.

[27]  J. Thiele,et al.  The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. , 2006, Seminars in thrombosis and hemostasis.

[28]  J. Thiele,et al.  Grade of bone marrow fibrosis is associated with relevant hematological findings—a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis , 2006, Annals of Hematology.

[29]  H. Kreipe,et al.  Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre‐staining processing of bone marrow biopsies , 2006, Histopathology.

[30]  J. Thiele,et al.  Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach. , 2005, Seminars in hematology.

[31]  J. Thiele,et al.  Hematopathologic findings in chronic idiopathic myelofibrosis. , 2005, Seminars in oncology.

[32]  G. Stein,et al.  Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. , 2005, Histology and histopathology.

[33]  M. Weiss,et al.  Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages , 2003, Annals of Hematology.

[34]  V. Diehl,et al.  Dynamics of Fibrosis in Chronic Idiopathic (Primary) Myelofibrosis During Therapy: A follow-up Study on 309 Patients , 2003, Leukemia & lymphoma.

[35]  G. Barosi.  Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Fischer,et al.  Prognostic factors in idiopathic (Primary) osteomyelofibrosis , 1997, Cancer.

[37]  A. Manoharan,et al.  The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults , 1979, British journal of haematology.

[38]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[39]  H. Puchtler,et al.  Silver impregnation methods for reticulum fibers and reticulin: A re-investigation of their origins and specifity , 1978, Histochemistry.

[40]  H. B. Marsden,et al.  Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood. , 1978, Journal of clinical pathology.

[41]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[42]  D. Bauermeister.  Quantitation of bone marrow reticulin--a normal range. , 1971, American journal of clinical pathology.

[43]  G. Gomori.  The effect of certain factors on the results of silver impregnation for reticulum fibers. , 1939, The American journal of pathology.

[44]  G. Gömöri.  Silver Impregnation of Reticulum in Paraffin Sections. , 1937, The American journal of pathology.

[45]  J. Gordon,et al.  Further observations on the general bactericidal action of normal serum , 1936 .

[46]  H. Gordon,et al.  A Simple Method for the Silver Impregnation of Reticulum. , 1936, The American journal of pathology.

[47]  S. Verstovsek,et al.  Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems , 2014, Modern Pathology.

[48]  J. Bussel,et al.  Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities , 2012, Modern Pathology.

[49]  A. Tefferi,et al.  Continuing medical education activity in American Journal of Hematology , 2011 .

[50]  Peter J Campbell,et al.  Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.

[51]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[52]  V. Diehl,et al.  Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. , 2004, Histology and histopathology.

[53]  H. Kreipe,et al.  Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. , 2003, American journal of clinical pathology.

[54]  J. Fleiss.  Measuring nominal scale agreement among many raters. , 1971 .